HYBRID NEUTROPHILS:
A Novel Universal Myeloid
Platform for Cancer Treatment
Hybrid neutrophils combine tumor-killing with immune activation —unlocking antibodies’ full potential in solid tumors
About
Revolutionary Myeloid Cell Therapy for Treatment-Resistant Solid Tumors
Hybrid Bio is a pioneering biotechnology company developing a first-in-class myeloid cell therapy platform designed to overcome the fundamental limitations of today’s immuno-oncology treatments. By harnessing a rare and powerful immune cell type — Hybrid (APC-like) Neutrophils—we aim to transform resistant solid tumors into curable diseases.
Current antibody therapies and immune checkpoint inhibitors often fail in solid tumors due to immune exclusion, T-cell exhaustion, and a hostile tumor microenvironment. Hybrid Bio addresses these barriers directly by bridging innate and adaptive immunity, enabling both rapid tumor cell killing and durable, tumor-specific immune memory.
Founded by a world-class team of immunologists, cell therapy innovators, and biotech executives, Hybrid Bio is advancing a pipeline led by a first-in-class program in EGFR-positive non-small cell lung cancer (NSCLC), with broad expansion potential across antibody-addressable solid tumors.
Science
Hybrid Neutrophils: A Dual-Function Super-Effector Cell
Originating from groundbreaking research by our Scientific Founder, Prof. Evgeniy Eruslanov (University of Pennsylvania), Hybrid Bio’s platform is built on the discovery of a rare, naturally occurring population of long-lived, antigen-presenting neutrophils found in early-stage solid tumors.
Unlike conventional immune effector cells, Hybrid Neutrophils combine:
-
Potent antibody-dependent tumor cell killing
-
Direct activation of adaptive, tumor-specific immunity
This unique biology enables a dual mechanism of action not achieved by existing cell therapies.
Mechanism of Action
-
Direct Tumor Elimination: High expression of functional Fc receptors enables powerful antibody-dependent cellular cytotoxicity (ADCC) against antibody-opsonized tumor cells.
-
Adaptive Immune Activation: Presentation of tumor-derived antigens via MHC class I and II primes both CD4⁺ and CD8⁺ T cells, generating durable anti-tumor immunity and immune memory.
Key Platform Advantages
-
Dual Mechanism of Action: Simultaneous innate killing and adaptive immune priming
-
Designed for Solid Tumors: Enhanced persistence and functionality within hostile tumor microenvironment
-
Native Antibody Compatibility: Works synergistically with approved and pipeline monoclonal antibodies
-
Repeat Dosing Potential: Unlike many engineered cell therapies
-
No Gene Editing: Proprietary ex vivo differentiation using FDA-approved reagents enables scalable, cost-effective manufacturing
-
Broad Pipeline Potential: Applicable across EGFR⁺ NSCLC, HER2⁺ breastcancer, EGFR⁺ head & neck cancer, EGFR⁺ colorectal cancer, and beyond
Human Biological Validation
Independent clinical and translational studies have identified Hybrid Neutrophils as the most beneficial tumor-associated neutrophil subtype across multiple solid tumors.
Elevated levels of these cells in the tumor microenvironment strongly correlate withimproved patient survival in CRC, NSCLC, STAD, RCC, ovarian, breast, and bladder cancers (Wu et al., Cell, 2024).
Preclinical Validation
-
Complete inhibition of tumor growth in multiple in vitro models with different therapeutic antibodies
-
Significant tumor volume reduction in A549 xenograft models in NSGS mice
-
Robust tumor antigen cross-presentation and tumor-specific T-cell activation in vitro
Our Team
Hybrid Bio is led by a multidisciplinary team with deep expertise across immunology, cell therapy development, CMC, regulatory strategy, and clinical oncology, with a proven track record of advancing complex biologics from discovery to the clinic.
Evgeniy Eruslanov, PhD
Scientific Founder & Advisor
World-recognized expert in myeloid cell biology and tumor immunology
Dr. Eruslanov is an Associate Professor at the University of Pennsylvania and a leading authority on neutrophil biology in cancer. His research led to the discovery of Hybrid APC-like Neutrophils and has been published in top-tier journals including Nature Immunology, Cancer Cell, and Science Translational Medicine. His work forms the
scientific foundation of Hybrid Bio’s platform.
Konstantin Kazarian, PhD
Co-founder & Chief Executive Officer
Co-Founder & Chief Executive Officer
Dr. Kazarian is an experienced biotech leader with a background in protein biochemistry and structural biology. After postdoctoral training, he transitioned into industry, holding roles from project management to VP-level leadership across leading CDMOs including Oxford Biomedica, Northway Biotech, Rentschler Biopharma, and Pyramid Labs. He brings extensive experience in CMC strategy, manufacturing scale-up, partnerships, and early-stage company building.
Christian Cunningham, CFA, MBA
Chief Business Officer
Seasoned corporate development and finance executive
Christian brings deep expertise in biotech finance, strategic transactions, and capital formation. He has held senior roles at G&W Laboratories, Pyramid Labs, and previously worked in investment banking at Rothschild and Bear Stearns. His experience spans private and public markets, M&A, and investor relations.
Haig Aghajanian, PhD
Science & Strategy Advisor
Proven biotech founder with multi-billion-dollar exit
Dr. Aghadjanian co-founded Capstan Therapeutics, where he oversaw scientific research until the company's acquisition by AbbVie for over $2 billion in 2025. Previously, as a postdoctoral researcher at UPenn, he made significant contributions to the scientific community, publishing widely in journals like Nature and Cell. Today, he serves as an Adjunct Assistant Professor at UPenn. Additionally, he advises Hybrid Bio on corporate strategy, platform development, and translating research into practical applications.
Deepthi Kolli, PhD
CMC & Quality Advisor
Cell therapy manufacturing and analytics veteran
Dr. Kolli has decades of experience in cell therapy process development, analytical development, and MSAT leadership. She has held senior roles at Atara Biotherapeutics, Sonoma Biotherapeutics, and Immpact Bio, where she served as VP of Process Development, Analytical Development, and MSAT.
Huafeng Wang, PhD
Scientific Advisor
Expert in translational immunology and preclinical development
Dr. Wang has led translational research programs in cell therapy at Shoreline Biosciences and previously conducted translational studies at Regulus Therapeutics and Scripps Research (Calibr). He brings deep expertise in bridging preclinical biology with clinical strategy.
Natalia Pripuzova, PhD
Regulatory & CMC Advisor
Former FDA regulator and cell & gene therapy Regulatory expert
Dr. Pripuzova brings over ten years of NIH, NCI and US FDA, CBER, OCTGT and CDER, OPQ experience combined with recent senior industry roles as Director and Head of Regulatory CMC at ADC Therapeutics and Shoreline Biosciences. Natalia is a CEO of NPDK Bioconsulting, a boutique Regulatory CMC Consulting firm and advises Hybrid Bio on regulatory strategy, IND preparation, and Regulatory Agencies engagement.
Lyudmila Bazhenova, MD
Clinical Advisor
Leader in thoracic oncology and clinical trial execution
Dr. Bazhenova is a thoracic oncologist and Director of the Hematology & Oncology Training Program at UC San Diego Moores Cancer Center. She has decades of experience leading lung cancer clinical trials and advising early-stage oncology programs on clinical strategy and trial design.
News
Jan 2026:
Hybrid Bio will participate in JP Morgan Healthcare Conference in San Francisco between Jan 12 and Jan 15. Please leave your contact information below to schedule a meeting with us.
Aug 2025:
Hybrid Bio moves into the new lab space at the University Lab Partners incubator in Irvine, CA.
Contacts
Join the Revolution
Hybrid Bio aims to revolutionize the treatment of some of the most challenging cancers. Keep an eye out for the updates on our advancements and join us on this pioneering journey.
Hybrid Biotherapeutics Inc., 5270 California Av. Suite 300, Irvine, CA 92617, USA
© 2026 by Hybrid Bio
